Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in ...
An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway SCLC is aggressive and ...
On average, cold emails only have a 0.9% response rate. It’s hard to stand out in a crowded inbox, and it’s only going to get harder. New email sender guidelines have been out for a couple years now.
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...